Because IGF-1R, Src, and AXL are potential cellular targets of LL6 in NSCLC cells, we assessed whether LL6 has comparable or superior antitumor activities compared with the concurrent blockade of IGF-1R, Src, and AXL by combined treatment with small molecular TKIs against IGF-1R (linsitinib), Src-family kinase (SFK, dasatinib), and AXL (bemcentinib). Here, SRC is linked to non-small cell lung carcinoma.